MTU Library Catalogue

Syndetics cover image
Image from Syndetics

Pharmacology / H. P. Rang, M. M. Dale, J. M. Ritter.

By: Rang, H. P.
Contributor(s): Dale, M. Maureen | Ritter, James.
Material type: materialTypeLabelBookPublisher: Edinburgh: Churchill Lovingstone, 1999Edition: 4th ed.Description: x, 830p.; ill., 25cm.ISBN: 0443059748; 9780443059742.Subject(s): Pharmacology | Health and Wellbeing | PharmacologyDDC classification: 615.1 RAN
Contents:
Section 1.General principles -- 1. How drugs act: general principles -- 2. How drugs act; molecular aspects-- 3. Method and measurement in pharmacology -- 4. Absorption and distribution of drugs -- 5. Drug elimination and pharmacokinetics -- Section 2: Chemical mediators -- 6. Chemical mediators and the autonomic nervous system -- 7. Cholinergic transmission -- 8. Noradrenergic transmission -- 9. Other peripheral mediators: 5-hydroxytryptamine and purines -- 10. Peptides and proteins as mediators -- 11. Nitrico oxide -- 12. Local hormones, inflammation and allergy -- 13. Anti-inflammatory and immunosuppresant drugs -- Section 3.Drugs affecting major organ systems -- 14.The heart -- 15. The vascular system -- 16. Atherosclerosis and lipoprotein metabolism -- 17. Haemostatis and thrombosis -- 18. The haemopoietic system -- 19. The respiratory system -- 20. The kidney -- 21. The gastrointestinal sysstem -- 22. The endocrine pancreas and the control of blood glucose -- 23. Obesity -- 24. The epituitary and adrenal cortex -- 25.The thyroid -- 26.The reproductive system -- 27. Bone metabolism -- Section 4:The central nervous sytem -- 28. Chemcial transmission and drug action in the central nervous system -- 29. Amino acid transmitters -- 30. Other transmitters and modulators -- 31. Neurodegenerative disorders -- 32. General anaesthetic drugs -- 33.Anxiolytic and hypnotic drugs -- 34. Antipsychotic drugs -- 35. Drugs used in affective disorders -- 36.Antiepileptic drugs and centrally acting muscle relaxants -- 37. Analgesic drugs -- 38. Central nervous system stimulants and psychotomimetic drugs -- 39. Drug dependence and drug abuse -- 40. Local anaesthetics and other drugs that affect ion channels -- Section 5: Chemotherapy of infectious and malignant disease -- 41. Basic principles of chemotherapy -- 42. Cancer chemotherapy -- 43. Antibacterial drugs -- 44. Antiviral drugs -- 45. Antifungal drugs -- 46. Antiprotozoal drugs -- 47. Anthelminthic drugs -- Section 6: General topics -- 48. Individual variation and drug interaction -- 49. Harmful effects of drugs -- 50.Gene therapy.
Summary: Providing students with an overview of how a class of drugs will be used in a clinical situation, this text covers physiology and biochemistry as well as pharmacology. It explains how drugs act and relates them to their effects and clinical uses.
Holdings
Item type Current library Call number Copy number Status Barcode
General lending MTU Kerry North Campus Library First Floor Main 615.1 RAN (Browse shelf(Opens below)) 0 Available 38888000821433
General lending MTU Kerry North Campus Library First Floor Main 615.1 RAN (Browse shelf(Opens below)) 1 Available 38888000446405
General lending MTU Kerry North Campus Library First Floor Main 615.1 RAN (Browse shelf(Opens below)) 1 Available 38888000446413
Total holds: 0
Browsing MTU Kerry North Campus Library shelves, Shelving location: First Floor Main Close shelf browser (Hides shelf browser)

Enhanced descriptions from Syndetics:

The aim of this work is not only to describe what drugs do, but to emphasize the mechanisms by which they act - where possible at the cellular and molecular level. Therapeutic agents have a high rate of obsolescence and many new ones are introduced each year; an appreciation of the mechanisms of action of the class of drugs to which a new agent belongs provides a starting point for understanding and using intelligently.

Previous ed.: 1995.

Includes bibliographic references and index.

Section 1.General principles -- 1. How drugs act: general principles -- 2. How drugs act; molecular aspects-- 3. Method and measurement in pharmacology -- 4. Absorption and distribution of drugs -- 5. Drug elimination and pharmacokinetics -- Section 2: Chemical mediators -- 6. Chemical mediators and the autonomic nervous system -- 7. Cholinergic transmission -- 8. Noradrenergic transmission -- 9. Other peripheral mediators: 5-hydroxytryptamine and purines -- 10. Peptides and proteins as mediators -- 11. Nitrico oxide -- 12. Local hormones, inflammation and allergy -- 13. Anti-inflammatory and immunosuppresant drugs -- Section 3.Drugs affecting major organ systems -- 14.The heart -- 15. The vascular system -- 16. Atherosclerosis and lipoprotein metabolism -- 17. Haemostatis and thrombosis -- 18. The haemopoietic system -- 19. The respiratory system -- 20. The kidney -- 21. The gastrointestinal sysstem -- 22. The endocrine pancreas and the control of blood glucose -- 23. Obesity -- 24. The epituitary and adrenal cortex -- 25.The thyroid -- 26.The reproductive system -- 27. Bone metabolism -- Section 4:The central nervous sytem -- 28. Chemcial transmission and drug action in the central nervous system -- 29. Amino acid transmitters -- 30. Other transmitters and modulators -- 31. Neurodegenerative disorders -- 32. General anaesthetic drugs -- 33.Anxiolytic and hypnotic drugs -- 34. Antipsychotic drugs -- 35. Drugs used in affective disorders -- 36.Antiepileptic drugs and centrally acting muscle relaxants -- 37. Analgesic drugs -- 38. Central nervous system stimulants and psychotomimetic drugs -- 39. Drug dependence and drug abuse -- 40. Local anaesthetics and other drugs that affect ion channels -- Section 5: Chemotherapy of infectious and malignant disease -- 41. Basic principles of chemotherapy -- 42. Cancer chemotherapy -- 43. Antibacterial drugs -- 44. Antiviral drugs -- 45. Antifungal drugs -- 46. Antiprotozoal drugs -- 47. Anthelminthic drugs -- Section 6: General topics -- 48. Individual variation and drug interaction -- 49. Harmful effects of drugs -- 50.Gene therapy.

Providing students with an overview of how a class of drugs will be used in a clinical situation, this text covers physiology and biochemistry as well as pharmacology. It explains how drugs act and relates them to their effects and clinical uses.

Table of contents provided by Syndetics

  • Section 1 General Principles
  • 1. What is pharmacology? (p. 2)
  • Pharmacology in the 20th century (p. 3)
  • 2. How drugs act: general principles (p. 7)
  • The binding of drug molecules to cells (p. 7)
  • Desensitisation and tachyphylaxis (p. 19)
  • 3. How drugs act: molecular aspects (p. 22)
  • Targets for drug action (p. 22)
  • Receptor proteins (p. 26)
  • Ion channels as drug targets (p. 45)
  • Control of receptor expression (p. 47)
  • Receptors and disease (p. 48)
  • 4. Cellular mechanisms: excitation, contraction and secretion (p. 51)
  • Regulation of intracellular calcium levels (p. 51)
  • Excitation (p. 55)
  • Muscle contraction (p. 62)
  • Release of chemical mediators (p. 64)
  • Epithelial ion transport (p. 66)
  • 5. Cellular mechanisms: cell proliferation and apoptosis (p. 69)
  • Cell proliferation (p. 69)
  • Angiogenesis (p. 74)
  • Apoptosis and cell removal (p. 74)
  • Pathophysiological implications (p. 77)
  • Therapeutic implications (p. 77)
  • 6. Method and measurement in pharmacology (p. 80)
  • Bioassay (p. 80)
  • Animal models of disease (p. 84)
  • Clinical trials (p. 86)
  • Balancing benefit and risk (p. 89)
  • 7. Absorption and distribution of drugs (p. 91)
  • Translocation of drug molecules (p. 91)
  • Drug disposition (p. 97)
  • Drug absorption (p. 98)
  • Special drug delivery systems (p. 104)
  • 8. Drug elimination and pharmacokinetics (p. 106)
  • Drug metabolism (p. 106)
  • Renal excretion of drugs and drug metabolites (p. 111)
  • Biliary excretion and enterohepatic circulation (p. 113)
  • Pharmacokinetics (p. 114)
  • Section 2 Chemical Mediators
  • 9. Chemical mediators and the autonomic nervous system (p. 122)
  • Historical aspects (p. 122)
  • The peripheral nervous system (p. 123)
  • Some general principles of chemical transmission (p. 126)
  • Basic steps in neurochemical transmission: sites of drug action (p. 133)
  • 10. Cholinergic transmission (p. 136)
  • Muscarinic and nicotinic actions of acetylcholine (p. 136)
  • Acetylcholine receptors (p. 137)
  • Physiology of cholinergic transmission (p. 139)
  • Effects of drugs on cholinergic transmission (p. 143)
  • 11. Noradrenergic transmission (p. 161)
  • Classification of adrenoceptors (p. 161)
  • Physiology of noradrenergic transmission (p. 164)
  • Drugs acting on adrenoceptors (p. 168)
  • Drugs that affect noradrenergic neurons (p. 176)
  • 12. Other peripheral mediators: 5-hydroxytryptamine and purines (p. 184)
  • 5-hydroxytryptamine (p. 184)
  • Purines (p. 192)
  • 13. Peptides and proteins as mediators (p. 198)
  • General principles of peptide pharmacology (p. 198)
  • Biosynthesis and regulation of peptides (p. 202)
  • Peptide antagonists (p. 204)
  • Proteins and peptides as drugs (p. 205)
  • Concluding remarks (p. 206)
  • 14. Nitric oxide (p. 208)
  • Biosynthesis of nitric oxide and its control (p. 209)
  • Degradation and carriage of nitric oxide (p. 210)
  • Effects of nitric oxide (p. 212)
  • Therapeutic approaches (p. 213)
  • Clinical conditions in which nitric oxide may play a part (p. 214)
  • 15. Local hormones, inflammation and immune reactions (p. 217)
  • The components of the acute inflammatory reaction (p. 217)
  • The outcome of the inflammatory response (p. 228)
  • Mediators of inflammation and immune reactions (p. 229)
  • Current therapies based on manipulation of the immune response (p. 241)
  • Potential new therapies (p. 241)
  • 16. Anti-inflammatory and immunosuppressant drugs (p. 244)
  • Non-steroidal anti-inflammatory drugs (p. 244)
  • Antagonists of histamine (p. 252)
  • Drugs used in gout (p. 254)
  • Antirheumatoid drugs (p. 255)
  • Immunosuppressant drugs (p. 257)
  • Possible future developments (p. 260)
  • Section 3 Drugs Affecting Major Organ Systems
  • 17. The heart (p. 264)
  • Physiology of cardiac function (p. 264)
  • Drugs that affect cardiac function (p. 272)
  • 18. The vascular system (p. 285)
  • Vascular structure and function (p. 285)
  • Control of vascular smooth muscle tone (p. 286)
  • Vasoactive drugs (p. 292)
  • Clinical uses of vasoactive drugs (p. 298)
  • 19. Atherosclerosis and lipoprotein metabolism (p. 306)
  • Atherogenesis (p. 306)
  • Lipoprotein transport in the blood (p. 307)
  • Lipid-lowering drugs (p. 309)
  • 20. Haemostasis and thrombosis (p. 314)
  • Blood coagulation (p. 315)
  • Drugs that act on the coagulation cascade (p. 317)
  • Platelet adhesion and activation (p. 323)
  • Fibrinolysis (thrombolysis) (p. 327)
  • 21. The haemopoietic system (p. 330)
  • The haemopoietic system (p. 330)
  • Haematinic agents (p. 331)
  • Haemopoietic growth factors (p. 336)
  • 22. The respiratory system (p. 340)
  • The regulation of respiration (p. 340)
  • Disorders of respiration and the drugs used in treatment (p. 341)
  • 23. The kidney (p. 352)
  • Outline of renal function (p. 352)
  • The structure and function of the nephron (p. 352)
  • Drugs acting on the kidney (p. 362)
  • Drugs which alter the pH of the urine (p. 365)
  • Drugs which alter the excretion of organic molecules (p. 365)
  • 24. The gastrointestinal tract (p. 367)
  • The innervation and the hormones of the gastrointestinal tract (p. 367)
  • Gastric secretion (p. 368)
  • Vomiting (p. 372)
  • The motility of the gastrointestinal tract (p. 375)
  • Drugs for chronic inflammatory bowel disease (p. 377)
  • Drugs affecting the biliary system (p. 378)
  • 25. The endocrine pancreas and the control of blood glucose (p. 380)
  • Pancreatic islet hormones (p. 380)
  • Control of blood glucose (p. 385)
  • Diabetes mellitus and the drugs used in treatment (p. 385)
  • 26. Obesity (p. 394)
  • The homeostatic mechanisms controlling energy balance (p. 394)
  • Obesity as a health problem and possible treatments (p. 397)
  • 27. The pituitary and adrenal cortex (p. 404)
  • The pituitary and drugs used in therapy (p. 404)
  • The adrenal cortex and drugs used in therapy (p. 411)
  • 28. The thyroid (p. 421)
  • Synthesis, storage and secretion of thyroid hormones (p. 421)
  • Regulation of thyroid function (p. 422)
  • Actions of the thyroid hormones (p. 423)
  • Transport and metabolism (p. 424)
  • Abnormalities of thyroid function (p. 424)
  • Drugs used in diseases of the thyroid (p. 425)
  • 29. The reproductive system (p. 429)
  • Endocrine control of reproduction and modulating drugs (p. 429)
  • Drugs used for contraception (p. 439)
  • The uterus (p. 441)
  • Erectile dysfunction (p. 443)
  • 30. Bone metabolism (p. 446)
  • Bone structure and composition (p. 446)
  • Bone remodelling (p. 446)
  • Disorders of bone and the drugs used in treatment (p. 451)
  • Section 4 The Nervous System
  • 31. Chemical transmission and drug action in the central nervous system (p. 456)
  • Chemical signalling in the nervous system (p. 457)
  • Targets for drug action (p. 458)
  • Drug action in the central nervous system (p. 459)
  • The classification of psychotropic drugs (p. 460)
  • 32. Amino acid transmitters (p. 462)
  • Excitatory amino acids (p. 462)
  • Glutamate (p. 463)
  • Gamma-aminobutyric acid (p. 470)
  • Glycine (p. 473)
  • 33. Other transmitters and modulators (p. 474)
  • Noradrenaline (p. 475)
  • Dopamine (p. 476)
  • 5-Hydroxytryptamine (p. 480)
  • Acetylcholine (p. 483)
  • Purines (p. 485)
  • Histamine (p. 485)
  • Other CNS mediators (p. 485)
  • A final message (p. 488)
  • 34. Neurodegenerative disorders (p. 490)
  • Mechanisms of neuronal death (p. 490)
  • Ischaemic brain damage (p. 493)
  • Alzheimer's disease (p. 494)
  • Parkinson's disease (p. 497)
  • Huntington's disease (p. 501)
  • Neurodegenerative prion diseases (p. 501)
  • 35. General anaesthetic agents (p. 503)
  • Mechanism of action of anaesthetic drugs (p. 504)
  • The effects of anaesthetics on nervous system (p. 505)
  • Effects on the cardiovascular respiratory systems (p. 506)
  • Inhalation anaesthetics (p. 506)
  • Individual inhalation anaesthetics (p. 509)
  • Intravenous anaesthetic agents (p. 511)
  • 36. Anxiolytic and hypnotic drugs (p. 515)
  • The nature of anxiety and measurement of anxiolytic activity (p. 515)
  • Classification of anxiolytic and hypnotic drugs (p. 516)
  • Benzodiazepines (p. 517)
  • Benzodiazepine antagonists (p. 523)
  • Buspirone (p. 523)
  • Barbiturates (p. 523)
  • Other potential anxiolytic drugs (p. 524)
  • 37. Antipsychotic drugs (p. 525)
  • The nature of schizophrenia (p. 525)
  • Antipsychotic drugs (p. 528)
  • 38. Drugs used in affective disorders (p. 535)
  • The nature of depression (p. 535)
  • Theories of depression (p. 536)
  • Antidepressant drugs (p. 538)
  • Electroconvulsive therapy (p. 547)
  • Clinical effectiveness of antidepressant treatments (p. 548)
  • Mood-stabilising drugs (p. 548)
  • 39. Antiepileptic drugs (p. 550)
  • The nature of epilepsy (p. 550)
  • Mechanism of action of antiepileptic drugs (p. 553)
  • Antiepileptic drugs (p. 554)
  • Muscle spasm and centrally acting muscle relaxants (p. 559)
  • 40. Analgesic drugs (p. 562)
  • Neural mechanisms of pain (p. 562)
  • Analgesic drugs (p. 572)
  • New approaches (p. 583)
  • 41. CNS stimulants and psychotomimetic drugs (p. 585)
  • Convulsants and respiratory stimulants (p. 585)
  • Psychomotor stimulants (p. 587)
  • Psychotomimetic drugs (p. 591)
  • 42. Drug dependence and drug abuse (p. 594)
  • The nature of drug dependence (p. 595)
  • Nicotine and tobacco (p. 598)
  • Ethanol (p. 603)
  • Cannabis (p. 608)
  • 43. Local anaesthetics (p. 612)
  • Local anaesthetics (p. 612)
  • Other drugs that affect sodium channels (p. 616)
  • Section 5 Drugs Used in the Treatment of Infections and Cancer
  • 44. Basic principles of chemotherapy (p. 620)
  • The molecular basis of chemotherapy (p. 620)
  • Resistance to antibacterial drugs (p. 629)
  • 45. Antibacterial drugs (p. 635)
  • Antimicrobial agents that interfere with the synthesis or action of folate (p. 637)
  • Beta-lactam antibiotics (p. 639)
  • Antimicrobial agents affecting bacterial protein synthesis (p. 643)
  • Antimicrobial agents affecting topoisomerase II (p. 647)
  • Miscellaneous antibacterial agents (p. 648)
  • Antimycobacterial agents (p. 649)
  • Possible new antibacterial drugs (p. 652)
  • 46. Antiviral drugs (p. 654)
  • Background information about viruses (p. 654)
  • The host-virus interaction (p. 655)
  • HIV and AIDS (p. 657)
  • Antiviral drugs (p. 659)
  • 47. Antifungal drugs (p. 666)
  • Fungal infections (p. 666)
  • Drugs used for fungal infections (p. 666)
  • Potential new antifungal therapies (p. 670)
  • 48. Antiprotozoal drugs (p. 672)
  • Host-parasite interactions (p. 672)
  • Malaria (p. 673)
  • Pneumocystis pneumonia and its treatment (p. 682)
  • Amoebiasis and amoebicidal drugs (p. 682)
  • Leishmaniasis and leishmanicidal drugs (p. 683)
  • Trypanosomiasis and trypanosomicidal drugs (p. 684)
  • Trichomoniasis and trichomonicidal drugs (p. 684)
  • Toxoplasmosis and toxoplasmocidal drugs (p. 684)
  • New approaches to antiprotozoal therapy (p. 685)
  • 49. Anthelminthic drugs (p. 687)
  • Helminth infections (p. 687)
  • Anthelminthic drugs (p. 688)
  • Resistance to anthelminthic drugs (p. 691)
  • New approaches to anthelminthic therapy (p. 691)
  • 50. Cancer chemotherapy (p. 693)
  • The pathogenesis of cancer (p. 693)
  • General principles of action of cytotoxic anticancer drugs (p. 696)
  • Drugs used in cancer chemotherapy (p. 698)
  • Resistance to anticancer drugs (p. 706)
  • Treatment schedules (p. 707)
  • Techniques for dealing with emesis and myelosuppression (p. 707)
  • Possible future strategies for cancer chemotherapy (p. 707)
  • Section 6 Special Topics
  • 51. Individual variation and drug interaction (p. 712)
  • Effects of ethnicity (p. 712)
  • Effects of age (p. 713)
  • Effects of pregnancy (p. 714)
  • Genetic factors (p. 714)
  • Idiosyncratic reactions (p. 716)
  • Effects of disease (p. 717)
  • Drug interactions (p. 718)
  • 52. Harmful effects of drugs (p. 724)
  • Types of adverse drug reaction (p. 724)
  • Drug toxicity (p. 725)
  • 53. Gene therapy (p. 738)
  • Technical aspects (p. 739)
  • Safety (p. 743)
  • Therapeutic aspects (p. 743)
  • 54. Drug discovery and development (p. 747)
  • The preclinical stages (p. 747)
  • Clinical development (p. 749)
  • Commercial aspects (p. 750)
  • A final note (p. 750)
  • Appendix (p. 753)
  • Index (p. 761)